Lunsumio (mosunetuzumab): New important identified risk of Hemophagocytic Lymphohistiocytosis

A Dear Healthcare Professional Letter has been issued by Roche Singapore Pte Ltd to inform healthcare professionals that Hemophagocytic Lymphohistiocytosis (HLH) is a new important identified risk for LUNSUMIO. HLH is a life-threatening syndrome, and early detection and management is essential. HLH, including immune effector cell-associated HLH-like syndrome (IEC-HS), may resemble severe cytokine release syndrome (CRS), but with clinical differences from CRS including a delayed onset, rapid increases in serum ferritin, and differences in cytokine profile. For any case of suspected HLH, LUNSUMIO should be interrupted and treatment should be considered per current practice guidelines or ASTCT expert consensus guidelines. Consensus guidelines recommend frontline treatment with anakinra (an interleukin1 receptor antagonist), with or without corticosteroids. Expert consultation is recommended if HLH is suspected. The prescribing information of LUNSUMIO will be updated accordingly. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

13 Sep 2024

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.